KKR-backed Biosynth Carbosynth acquires Vivitide
KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide.
Investment firm KKR has closed its acquisition of UK life sciences company Biosynth Carbosynth, and announced Biosynth's acquisition of vivitide, which provides custom peptides and antibodies for the biotech industry.
Previous vivitide owner Ampersand Capital Partners will become a minority stakeholder in the combined entity. KKR and Ampersand say they plan to accelerate the company’s geographic expansion, broaden its capabilities and expand its product portfolio.
KKR utilized a $4 billion strategic growth fund focused on high-growth health care companies to invest in Biosynth Carbosynth. Company leadership believe the move will position Biosynth Carbosynth as a premium global platform serving high-growth end markets in the life sciences.
Speaking on the acquisition, Biosynth Carbosynth CEO Dr. Urs Spitz said the deal marks an “important milestone” in the company’s journey, adding that Biosynth will “benefit greatly from vivitide’s strong U.S. presence, complementary portfolio of products and services, and entrepreneurial culture.”
Vivitide CEO Dr. Martina Diekmann said she was proud to join forces with Biosynth, noting that the acquisition will allow an acceleration of growth and expanded product offering.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...